Latest Breaking News On - Therapeutics regulatory affairs - Page 1 : comparemela.com

Sapience Therapeutics has received ODD from the US FDA for its lead programme, ST101, to treat advanced melanoma for patients in stages IIB through IV.

Barry kappelGina capiauxSapience therapeutics regulatory affairsTherapeutics regulatory affairsOrphan drug designation